Magalí Alejandra LingenfelderMagalí Lingenfelder is currently leading the Max Planck-EPFL Laboratory for Molecular Nanoscience. Her vision is to create atomically tailored interfaces for applications in two distinct areas of urgent technological and societal relevance: energy conversion and smart antimicrobial interfaces. To access the nanoscale, her group uses a combination of state-of-the-art scanning probe microscopy and solid state spectroscopy, allowing the study of kinetic processes in-situ under liquid flow and potential control conditions (operando electrocatalysis). She made seminal contributions to the field of metal-organic coordination networks on solid surfaces, and received the Otto Hahn medal in 2008 for the microscopic understanding of the chiral recognition process with submolecular resolution. She is a committed mentor, and since her relocation from the Lawrence Berkeley National Laboratory, USA to EPFL in 2013, she directed 3 MSc. theses, 4 PhD theses and 4 postdocs. She advocates for problem-oriented interdisciplinary research: she led 5 international research consortiums, delivered over 40 invited presentations and organized 9 conferences and 4 doctoral schools. In 2018, the Royal Society of Chemistry included her work in the first collection “Celebrating Excellence in Research: 100 Women of Chemistry”.
Georges WagnièresGeorges Wagnières received his diploma degree (MSc) in physics from the University of Lausanne, Switzerland, in 1986. He obtained his doctorate in science (PhD) in physics (Biomedical optics) from the Swiss Federal Institute of Technology at Lausanne (EPFL) in 1992 and did a postdoctoral work in the Wellman Laboratories of Photomedicine (Harvard Medical School), Boston, USA, from 1993 to 1994. He also obtained a Master degree in Management of Technology delivered by the Ecole des Hautes Etudes Commerciales (HEC) of Lausanne University and the EPFL in 2001. Georges Wagnières manages a research group active in the fields of: - Detection of early superficial cancers by fluorescence imaging. - Characterization of early superficial cancers by high magnification narrow band imaging. - In vivo and in vitro measurement of the vascular and tissular oxygen concentration by time-resolved luminescence spectroscopy and imaging. - Preclinical and clinical study of new photosensitizers for photodynamic therapy (PDT). - Treatment of neurodegenerative conditions (Alzheimer, Parkinson's diseases) by photobiomodulation. - Preclinical and clinical photodynamic therapy of inflammatory bowel diseases and atheroscerotic plaque. - Improvement of the selective vascular extravasation of chemotherapeutic agents by PDT. - Monitoring the light dosimetry during PDT by fluorescence spectroscopy and imaging. - Monitoring laser treatments of the retina by reflectance imaging. - Light dosimetry and tissue optical spectroscopy. - Radiometry. - Development of light delivery systems for biomedical applications. Georges Wagnières is also co-founder and was chairman of one spin-off companies: - Medlight SA, founded in July 1997, which develops, produces and commercializes light distributors for photodynamic therapy. Georges Wagnières has currently authored more than 235 papers (more than 150 in international journals with review board) and is inventor of 18 patents. He supervised 12 PhD students up to now, and currently teaches biomedical optics and photomedicine in master programs and doctoral schools. In addition, he gives the course entitled "Physique Générale I" to biology first year students registered to the Biology School of the Lausanne's University. MAIN PUBLICATIONS Please visit: https://www.epfl.ch/labs/lifmet/wagnieres/publications/ Hatice Altug2020-current Full Professor at the Institute of Bioengineering, EPFL, Switzerland2013-2020 Associate Professor (with tenure) at the Institute of Bioengineering, EPFL, Switzerland 2013 Associate Professor (with tenure) at Electrical and Computer Engineering Department of Boston University, USA 2007-2013 Assistant Professor (tenure-track) at Electrical and Computer Engineering Department of Boston University, USA 2007 Post-doctoral Fellow at Center for Engineering in Medicine of Harvard Medical School, USA 2000-2007 PhD. in Applied Physics at Stanford University, USA 1996-2000 B.S. in Physics at Bilkent University, Turkey
Andrew Charles OatesAfter an undergraduate degree in Biochemistry at the University of Adelaide with Honours in Robert Saint’s lab, Andrew Oates received his Ph.D. at the Ludwig Institute for Cancer Research and the University of Melbourne in the lab of Andrew Wilks. His postdoctoral time was at Princeton University and the University of Chicago in the lab of Robert Ho, where his studies on the segmentation clock in zebrafish began in 1998. In 2003 he moved to Germany and started his group at the Max Planck Institute for Molecular Cell Biology and Genetics in Dresden. In 2012 he accepted a position at University College London as Professor of vertebrate developmental genetics and moved his group to the MRC-National Institute for Medical Research at Mill Hill in London. From April 2015, he became a member of the Francis Crick Institute in London. In September 2016, he joined École polytechnique fédéral de Lausanne (EPFL) in Switzerland as a Professor, where he is the head of the Timing, Oscillation, Patterns Laboratory. From April 2018 he served as Director of the Institute of Bioengineering, and from January 2021 became the Dean of the School of Life Sciences.
The Timing, Oscillation, Patterns Laboratory is composed of biologists, engineers, and physicists using molecular genetics, quantitative imaging, and theoretical analysis to study a population of coupled genetic oscillators in the vertebrate embryo termed the segmentation clock. This system drives the rhythmic, sequential, and precise formation of embryonic body segments, exhibiting rich spatial and temporal phenomena spanning from molecular to tissue scales.
